Latest on Anabolic Agents for Osteoporosis Treatment

被引：2
|
作者：
di Filippo, Luigi [1 ,2 ]
Rosen, Clifford J. [3 ]
机构：
[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期
关键词：
Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;
D O I：
10.1016/j.ecl.2024.08.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.
引用
收藏
页码：513 / 523
页数：11
相关论文
共 50 条
  • [1] Emerging anabolic agents in the treatment of osteoporosis
    Lovato, Christina
    Lewiecki, E. Michael
    EXPERT OPINION ON EMERGING DRUGS, 2017, 22 (03) : 247 - 257
  • [2] Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments
    Dede, Anastasia D.
    Makras, Polyzois
    Anastasilakis, Athanasios D.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1137 - 1144
  • [3] Anabolic therapy for osteoporosis: update on efficacy and safety
    Bandeira, Leonardo
    Lewiecki, E. Michael
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (05): : 707 - 716
  • [4] The use of anabolic agents in the treatment of osteoporosis: a clinical update
    Inderjeeth, Charles A.
    Inderjeeth, Diren C.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2024, 31 (04) : 157 - 163
  • [5] Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
    Cosman, Felicia
    Dempster, David W.
    CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (02) : 189 - 205
  • [6] New anabolic therapies for osteoporosis
    Minisola, Salvatore
    Cipriani, Cristiana
    Occhiuto, Marco
    Pepe, Jessica
    INTERNAL AND EMERGENCY MEDICINE, 2017, 12 (07) : 915 - 921
  • [7] Anabolic agents: what is beyond osteoporosis?
    Liu, Y.
    Levack, A. E.
    Marty, E.
    Or, O.
    Samuels, B. P.
    Redko, M.
    Lane, J. M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (05) : 1009 - 1022
  • [8] The evolving role of anabolic therapy in the treatment of osteoporosis
    Cosman, Felicia
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (04) : 376 - 380
  • [9] The role of osteoanabolic agents in the management of patients with osteoporosis
    McClung, Michael R.
    Rothman, Micol S.
    Lewiecki, E. Michael
    Hanley, David A.
    Harris, Steven T.
    Miller, Paul D.
    Kendler, David L.
    POSTGRADUATE MEDICINE, 2022, 134 (06) : 541 - 551
  • [10] Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
    Toulis, Konstantinos A.
    Anastasilakis, Athanasios D.
    Polyzos, Stergios A.
    Makras, Polyzois
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2011, 10 (03): : 174 - 195
12345